Adia Nutrition (ADIA) Receivables (2025 - 2026)
Adia Nutrition's (ADIA) quarterly Receivables came in at $44010.0 in Q2 2026, down 44.54% quarter-over-quarter from $79360.0 in Q1 2026.
Powered by 
Analysis
Adia Nutrition (ADIA) Receivables (2025 - 2026) Analysis & Trends
Adia Nutrition (ADIA) has reported Receivables for 2 consecutive years, with $44010.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Receivables changed N/A year-over-year to $44010.0 in Q2 2026; TTM through Jun 2026 was $44010.0, a N/A change from a year earlier, with the FY2025 full-year figure at $33360.0, up 233.6% from the prior year.
- Receivables was $44010.0 for Q2 2026 at Adia Nutrition, down from $79360.0 in the prior quarter.
- Over five years, Receivables peaked at $79360.0 in Q1 2026 and troughed at $33360.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 9.96 Bn | 9.12 Bn | 112.79 Mn | 138.70 Mn |
| 2 | CRISPR Therapeutics AG | 5.47 Bn | 5.47 Bn | - | - |
| 3 | Iovance Biotherapeutics | 4.64 Bn | 4.35 Bn | 55.72 Mn | 102.12 Mn |
| 4 | Legend Biotech | 3.25 Bn | 2.28 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 5.78 Mn |
| 6 | Precigen | 2.79 Bn | 2.79 Bn | 52.17 Mn | 72.04 Mn |
| 7 | Beam Therapeutics | 2.58 Bn | 2.58 Bn | - | - |
| 8 | Sarepta Therapeutics | 2.12 Bn | 1.33 Bn | 251.87 Mn | 421.82 Mn |
| 9 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 75.71 Mn |
| 10 | Adia Nutrition | 11.33 Mn | 11.33 Mn | - | 44,010.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44,010.00 |
| Mar 31, 2026 | 79,360.00 |
| Dec 31, 2025 | 33,360.00 |